• Skip to primary navigation
  • Skip to main content
  • Skip to footer
Neurotech International

Neurotech International

ASX:NTI

  • Home
  • Corporate
    • Board and Management
    • Corporate Directory
    • Corporate Governance
  • Development Programs
    • Biopharmaceutical Trials
    • Combination Therapy
    • Pathways to Commercialisation
    • Mente Technology
  • Investors
    • Investor Dashboard
    • ASX Announcements
    • Company Reports
    • Presentations
    • Research
    • News & Media
  • Contact

Kalkine Media

RSH, AVR, NTI: Best performing ASX healthcare equipment stocks in June

28 June 2022 News & MediaKalkine Media

Neurotech is conducting clinical studies to assess the anti-inflammatory, neuroprotective, and neuro-modulatory activities of its proprietary NTI/Dolce cannabis strains.

Footer

Suite 5 CPC, 145 Stirling Highway
Nedlands WA 6009
Australia

moc.l1675266414anoit1675266414anret1675266414nihce1675266414torue1675266414n@ofn1675266414i1675266414

+61 (8) 9389 3130

Subscribe to our latest announcements

Name*
This field is for validation purposes and should be left unchanged.

Copyright © 2023 Neurotech International • Site by White Noise Communications

Download prospectus